Kala Bio (KALA) Gains from Investment Securities (2016 - 2017)
Kala Bio (KALA) posted Gains from Investment Securities of $623000.0 for Q3 2017, down 47.43% sequentially from $1.2 million in Q2 2017, and up 402.43% YoY from $123998.1 in Q3 2016.
Kala Bio (KALA) Gains from Investment Securities (2016 - 2017) Analysis & Trends
Kala Bio has reported Gains from Investment Securities for 2 years, with the latest figure at $623000.0 in Q3 2017.
- Quarterly Gains from Investment Securities rose 402.43% year-over-year to $623000.0 in Q3 2017, while the trailing twelve-month figure through Dec 2017 was $1.8 million (changed N/A YoY) and the FY2017 annual result came in at $1.8 million, up 1611.48% from the prior year.
- Gains from Investment Securities eased to $623000.0 in Q3 2017 per KALA's latest filing, from $1.2 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $1.2 million in Q2 2017 and troughed at -$206000.0 in Q3 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Kala Bio | 9.89 Mn | 9.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 623,000.00 |
| Sep 30, 2017 | 623,000.00 |
| Jun 30, 2017 | 1.19 Mn |
| Jun 30, 2017 | 1.19 Mn |
| Mar 31, 2017 | 36,000.00 |
| Mar 31, 2017 | 36,000.00 |
| Dec 31, 2016 | 55,000.00 |
| Dec 31, 2016 | 55,000.00 |
| Sep 30, 2016 | -206,000.00 |
| Sep 30, 2016 | -206,000.00 |
| Jun 30, 2016 | 47,000.00 |
| Jun 30, 2016 | 47,000.00 |